ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
COVID vaccines

Moderna finds stainless steel particles in shots pulled in Japan

US drugmaker and distributor Takeda say no undue risk to public

The 1.6 million doses of Moderna's vaccine were withdrawn for containing particles of stainless steel, likely due to misaligned bottling components, (Photo by Shinya Sawai)

TOKYO -- Vials of coronavirus vaccine developed by Moderna contained particles of stainless steel, the U.S. drugmaker said Wednesday in a statement with Japanese distributor Takeda Pharmaceutical, revealing why roughly 1.6 million doses in Japan were withdrawn.

The particles do "not pose an undue risk to patient safety," and they "are unlikely to result in other adverse reactions beyond the local site of the injection," according to the statement.

The statement, which follows an investigation by Takeda, Moderna and the vaccine maker's Spanish production partner, comes after reports of particulate matter in vials prompted Japan's health ministry to halt injections from the lot in question on Aug. 26. Two other lots produced at the same plant around the same time also were withdrawn.

A Takeda spokesperson also said there were "no safety problems" with the vaccine.

Two people in Japan who received doses from these lots later died. The companies called the deaths "tragic" but said they appear to be "coincidental," with no evidence connecting them to the vaccine.

"It is important to conclude a formal investigation to confirm this," the statement said. "The investigation is being conducted with the greatest sense of urgency, transparency and integrity and is of the highest priority."

The stainless steel particles likely came from improperly aligned components on the vaccine bottling line, the companies said. The problem was limited to the three lots already withdrawn, according to the statement.

Takeda begins a recall of the three lots on Thursday.

The health ministry said it will consider any administrative actions against Takeda, Japan's biggest drugmaker, based on the findings of the investigation.

All Nippon Airways and a number of local governments halted use of the Moderna inoculation after the ministry's Aug. 26 action. The Moderna vaccine was granted emergency-use authorization in Japan in May.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more